Augment Biologics

Augment Biologics is a platform-enabled biopharmaceutical company using foundational discoveries in glycobiology to transform biologic drug development. The company developed GlycoTemplating, an AI-guided glycoprotein-drug design platform that writes glycans directly into the primary protein sequence with site-specific accuracy. Unlike traditional glycoengineering methods, GlycoTemplating is expression-platform-agnostic and improves drug efficacy, safety, durability, and manufacturability. The platform is built on discoveries in glycan biosynthesis from the Lewis Lab at UCSD and the University of Georgia. Near-term applications focus on antibody, protein, and peptide engineering; long-term applications extend to RNA therapeutics, delivery vehicles, and vaccine development. In 2025, the company joined the Recode Ventures Edge cohort and was selected for MassBio Drive.